SCHEMBL1304909

SCHEMBL1304909

FC(F)(F)Cn1cccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.38
TSHR P16473 1/20 0.36
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
AR P10275 1/20 0.33
DAO P14920 1/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
HTT P42858 1/20 0.32
BRD4 O60885 1/20 0.31
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
ADORA2A P29274 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451536 0.82 FDPS (0.36) FDPSTSHRCYP3A4GAAMAPT
SCHEMBL29268091 0.82 AR (0.37) FDPSTSHRCYP3A4GAAMAPT
SCHEMBL3294905 0.79 CYP3A4 (0.38) FDPSTSHRCYP3A4GAAMAPT
SCHEMBL19992033 0.77 LMNA (0.38) FDPSTSHRGAAMAPTLMNA
SCHEMBL14451165 0.76 FDPS (0.38) FDPSTSHRCYP3A4GAAMAPT
SCHEMBL309198 0.76 FDPS (0.38) FDPSTSHRCYP3A4GAAMAPT
SCHEMBL3980897 0.74 AR (0.34) TSHRAR
SCHEMBL13315230 0.74 CYP3A4 (0.36) FDPSTSHRCYP3A4LMNAPOLB
SCHEMBL16815831 0.74 DAO (0.39) FDPSTSHRGAAMAPTLMNA
SCHEMBL28257309 0.73 FDPS (0.31) FDPSCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070879-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2026-03-12 US claimed
US-20240308980-A1 HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-09-19 US claimed
US-20240174679-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2024-05-30 US claimed
WO-2023071218-A1 PYRAZOLOPYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 沈阳药科大学 2023-05-04 WO claimed
CN-115137726-A Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2022-10-04 CN claimed
CN-115073421-A Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2022-09-20 CN claimed
CN-115068468-A Carboxylic aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2022-09-20 CN claimed
CN-110325523-B Carboxylic acid aromatic amides as bradykinin B1 receptor antagonists 拜耳制药股份公司 2022-07-26 CN claimed
EP-2968233-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI Foundation, Inc. (US) 2016-01-20 EP claimed
WO-2014159224-A1 HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION, INC. (US) 2014-10-02 WO claimed
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 US disclosed
EP-4646410-A1 TUBULIN POLYMERIZATION INHIBITORS AB Science (FR) 2025-11-12 EP disclosed
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 US disclosed
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-09-02 US disclosed
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2025-06-19 US disclosed
CN-102762548-A Isoindolinone inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMA 2012-10-31 CN disclosed
US-20110269770-A1 Pyrazole Compounds for Controlling Invertebrate Pests BASF SE (DE) 2011-11-03 US disclosed
CN-101362753-A Sulfonyl isoxazole derivates with obvious herbicidal activity INST PLANT PROTECTION IPP CAAS (CN) 2009-02-11 CN disclosed
EP-1987003-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2007093542-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308980-A1 HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, BRSK2 FDPS 3161/4885TSHR 4238/4885CYP3A4 4286/4885
US-20110269770-A1 Pyrazole Compounds for Controlling Invertebrate Pests GRIN2C, GRIN2D, NR2C2 FDPS 3402/4885TSHR 766/4885CYP3A4 702/4885
US-20240174679-A1 HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF LRRK2, CLK2, BRSK2 FDPS 3202/4885TSHR 4052/4885CYP3A4 3162/4885
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS EED, EZH2, BMI1 FDPS 4751/4885TSHR 2892/4885CYP3A4 2085/4885
US-20260070879-A1 ISOXAZOLINE DERIVATIVES CHRM1, CBR3, AFF1 FDPS 3360/4885TSHR 45/4885CYP3A4 980/4885
US-12404266-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 FDPS 1358/4885TSHR 3289/4885CYP3A4 2713/4885
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 FDPS 656/4885TSHR 3622/4885CYP3A4 2682/4885
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM6, TRPV3, TRPM2 FDPS 3682/4885TSHR 642/4885CYP3A4 1405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.